http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
상업용 도시재생 모듈러 건축물의 공간이용에 따른 실내공기질 평가
남소정,김세련,평우진,강유진,김수민 한국가구학회 2016 한국가구학회지 Vol.27 No.3
From 2000s, modular construction has gained more attention due to many advantages such as reduction of duration, recycling. The modular structure is being used for urban regeneration recently. However, even though most facilities in the modular structures which are used as urban regeneration building are commercial spaces, exhibition spaces, eating and drinking spaces, there are lack of natural or mechanical ventilation systems. Also, there are relatively limited spaces on modular structure characteristic. Therefore, indoor environment performance of four buildings, which are performed as urban regeneration in Seoul, was evaluated by HCHO and CO2 emissions. Consequently, the HCHO and CO2 emissions of the commercial and exhibition spaces were confirmed that can influence on health of occupants. Therefore, the urban regeneration modular structure needs to add local ventilation systems for improvement of indoor air quality to more healthy and comfortable.
Clinical Efficacy of Pimobendan on Dogs with Chronic Mitral Valvular Diseases
남소정,박인철,현창백 한국임상수의학회 2009 한국임상수의학회지 Vol.26 No.1
Pimobendan is a recently developed cardiac drug which is useful to control moderate to severe congestive heart failure (CHF) from chronic mitral valvular diseases (CMVI). Because of controversy related to the efficacy and safety of pimobendan in dogs, the optimal efficacy and safety of pimobendan was assessed in 20 dogs with CMVI in this study. Scores for quality of life, respiratory failure, circulatory failure and heart failure were evaluated along with radiographical and echocardiographical assessments for about 2 months period after the addition of pimobendan into the regular cardiac medications. This study proved clear evidence that pimobendan had beneficial therapeutic effects in dogs with advanced CMVI, without particular adverse effects. However, further studies are warranted to address the drug interaction with other cardiac therapeutics and to assess therapeutic effects in CHF from other type of heart diseases in dogs and other animals.
Peritoneal Dialysis in Dogs: 20 cases (2006-2008)
남소정,최란,현창백,오원석 한국임상수의학회 2009 한국임상수의학회지 Vol.26 No.1
Peritoneal dialysis (PD) is a clinical technique that therapeutically removes toxic solutes from body fluids and normalizes endogenous solutes whose aberrant concentrations disrupt normal physiology. This study retrospectively evaluated clinical outcomes and complications of PD in 20 dogs with renal failure. Blood works (total count of red blood cells (RBC), packed cell volume (PCV), the serum biochemical, and electrolyte values related to renal insufficiency) and complications associated with peritoneal dialysis, and clinical outcomes were recorded before and after PD. Additionally, creatinine reduction ratio (CRR) and urea nitrogen reduction ratio (URR) were calculated for evaluating the efficacy of PD. PD resulted in a significant (p < 0.05) reduction in blood urea nitrogen (BUN) concentration in 19 dogs, while a significant (p < 0.05) reduction in creatinine concentration in 17 dogs. The complications of PD were hypoalbuminemia (12/20, 60%), anemia (10/20, 50%), subcutaneous dialysate leakage (9/ 20, 45%), bacterial peritonitis (6/20, 30%), dialysate retention (5/20, 25%) and limb edema (4/20, 20%). This study demonstrated that PD was effective in reducing the magnitude of azotemia in dogs with renal failure especially in acute phase, although the complication rate was high but manageable.
남소정,현창백 한국임상수의학회 2009 한국임상수의학회지 Vol.26 No.2
Patent ductus arteriosus (PDA) is an abnormal shunt between the descending aorta and pulmonary artery through the incompletely closed ductus arteriosus and is the most common congenital heart defect in dogs. Recent human genetic studies found that a the gene mutation in transcription factor AP-2 beta (TFAP2B) was responsible for syndromic cases of PDA. Mutations in the TFAP2B gene are associated with certain congenital cardiac defects in humans that include PDA. In this study, we isolated the entire coding exons of canine TFAP2B gene for genetic screening in dogs with PDA. Analysis of the deduced amino acid sequence suggested that the canine TFAP2B are phylogenetically closer to the human TFAP2B (100% identity in amino acid sequence) than mouse and rat. In cTFAP2B gene screening, one single c.936 + 203G > A base change was found in affected Maltese dogs with PDA. However, further screening found the same base change in one unaffected control dog, suggesting this base change might be polymorphism. No other base changes were found in other dog breeds enrolled in this study. Because the base change was located in the intronic region and found in an unaffected control dog, TFAP2B might not be responsible for familial PDA in Malteses and sporadic cases of other dog breeds, although the gene promoter region should be investigated before reaching to this conclusion. A future study that may take this study further would be to collect more samples and to screen TFAP2B in various breeds of dogs with PDA and other various congenital heart defects.
Sinoatrial Reentrant Tachycardia in a Yorkshire Cross Dog
남소정,현창백 한국임상수의학회 2008 한국임상수의학회지 Vol.25 No.5
An 8-year-old intact male Yorkshire cross dog (7.5 kg of body weight) was referred with the primary complaint of exercise intolerance and occasional syncope. Initial cardiological examination could not identify any abnormalities except mild mitral regurgitation. Exercise stress test revealed chronotrophic incompetence. Furthermore the 1 hr-digital event recording found the sudden onset of paroxysmal sinus tachycaridas (156-172 bpm) lasting few minutes and stopping abruptly. In addition, the tachycardia terminated by vagal maneuver and verapamil administration. Based on this finding, the case was diagnosed as sinoatrial reentrant tachycardia (SART). The dog was treated with diltiazem and enalapril. Although the dog still has exercise intolerance, no syncope has been observed after medication.
남소정,이태호,최민구,송임숙 사단법인 한국질량분석학회 2018 Mass spectrometry letters Vol.9 No.2
KPLA-012, a benzopyranyl 1,2,3-triazole compound, is considered a potent HIF-1α inhibitor based on the chemical library screening, and is known to exhibit anti-angiogenetic and anti-tumor progressive effects. The aim of this study was to investigate the pharmacokinetic properties of KPLA-012 in ICR mice and to investigate in vitro characteristics including the intestinal absorption, distribution, metabolism, and excretion of KPLA-012. The oral bioavailability of KPLA-012 was 33.3% in mice. The pharmacokinetics of KPLA-012 changed in a metabolism-dependent manner, which was evident by the low recovery of parent KPLA-012 from urine and feces and metabolic instability in the liver microsomes. However, KPLA-012 exhibited moderate permeability in Caco-2 cells (3.1 × 10 -6 cm/s) and the metabolic stability increased in humans compared to that in mice (% remaining after 1 h; 47.4% in humans vs 14.8% in mice). Overall, the results suggest that KPLA-012 might have more effec- tive pharmacokinetic properties in humans than in mice although further studies on its metabolism are necessary.